Skip to main content

Table 2 Characteristics of participants

From: Effects of a community-based salt reduction program in a regional Australian population

  Baseline Follow-up
  Random (n = 306) Volunteer (n = 113) Random followed from baseline (n = 101) Random new (n = 106) Volunteer followed from baseline (n = 36) Volunteer new (n = 329) P value*
Female (%) 53 61 56 61 61 58 0.25
Age, years range (mean) 20–88 (58) 20–84 (49) 29–90 (64) 21–90 (60) 22–83 (60) 20–89 (52) 0.49‡
Height, cm mean (SD) 168 (10) 167 (8.8) 166 (9.6) 166 (10.2) 168 (8.9) 167 (10) 0.38
Weight, kg mean (SD) 82 (17.1) 84 (20.6) 82 (16.9) 84 (24.1) 86 (26) 82 (19.9) 0.90
BMI, kg/m2 mean (SD) 29 (5.1) 30 (6.6) 29 (5.9) 30 (7.0) 30 (8.3) 29 (6.6) 0.45
Systolic bp, mmHg mean 127 124 127 133 131 126 0.10
Diastolic bp, mmHg mean 79 79 78 81 82 80 0.27
Creatinine mmol mean (SD) 12.0 (3.8) 12.0 (4.2) 11.0 (3.6) 12.0 (4.3) 12 (3.8) 12 (4.4) 0.31
Urine volume, ml mean (SD) 1930 (808) 2012 (868) 1957 (859) 2082 (875) 1867 (747) 1930 (823) 0.94
Education (%)        0.01
Secondary 64 56 55 49 50 45  
Tertiary 26 33 40 46 44 47  
Postgraduate 10 12 5 5 6 8  
Health Status (%)
Very good 50 49 33 30 19 31 0.12
Good 30 24 42 44 42 43  
Fair 20 27 25 26 39 26  
Smoking status (%)
Current smoker (>1/day) 8 22 7 6 14 18 0.67
Ever smoked (>1/day) 41 53 37 39 50 42  
Alcohol consumption (time since last drink) One week or less 62 43 58 58 40 53  
12 months or more 38 57 42 42 60 47 0.20
Have you ever been told by a nurse of doctor that you have (%)
High blood pressure 44 30 55 42 50 40 0.02
Heart attack 8 4 11 9 6 3 0.62
Stroke 4 2 6 3 3 2 0.57
Angina 7 4 8 7 11 5 0.93
Diabetes 11 7 13 15 11 11 0.25
Prescription Medication † (%)
Antihypertensive 22 20 37 31 26 23 0.03
Lipid lowering 16 18 30 22 14 17 0.20
Aspirin 8 3 21 14 9 8 0.01
Glucose lowering 5 9 9 11 12 7 0.13
Any prescription medication 66 53 79 83 60 60 0.10
  1. *Age comparison presented is for the new random and volunteer sample with the baseline sample, excluding paired participants (the same random and volunteer sample sampled at baseline at follow-up)
  2. Participants could be taking more than one prescribed medication
  3. p-value compared mean values across all baseline vs. all follow-up